达格列净二甲双胍缓释片在中国健康受试者的等效性研究

叶茜 ,  刘一乔 ,  吴轩宇 ,  王一琪 ,  李帆 ,  李宏宇 ,  孟祥云 ,  王凤玲

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1231 -1237.

PDF (652KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1231 -1237. DOI: 10.12092/j.issn.1009-2501.2026.09.009

达格列净二甲双胍缓释片在中国健康受试者的等效性研究

作者信息 +

Equivalence study of dapagliflozin metformin extended-release tablets in healthy subjects in China

Author information +
文章历史 +
PDF (667K)

摘要

目的: 比较达格列净二甲双胍缓释片在中国健康人体内的生物利用度和生物等效性。方法: 采用 HPLC-MS/ MS 法测定血浆中达格列净及二甲双胍浓度,采用 WinNonlin 软件(8.2 版本)和 SAS 9.4 软件分析生物等效性。结果: 空腹条件下,单剂量口服达格列净二甲双胍缓释片(10 mg/1 000 mg)受试制剂或参比制剂后,血浆中达格列净的 Cmax、AUC0-t、AUC0-∞几何均数比值与 90% 置信区间分别是 109.18%(101.89%~116.99%)、102.17%(99.37%~105.04%)与101.92%(98.94%~104.99%),血浆中二甲双胍的 Cmax、AUC0-t、AUC0-∞几何均数比值与 90% 置信区间分别是 101.85% (96.67%~107.30%)、100.51%(95.36%~105.95%)与 100.03%(94.94%~105.39%)。餐后条件下,单剂量口服达格列净二甲双胍缓释片(10 mg/1 000 mg)受试制剂或参比制剂后,血浆中达格列净的 Cmax、AUC0-t、AUC0-∞几何均数比值与 90% 置信区间分别是 98.27%(88.80%~108.74%)、103.09%(99.17%~107.16%)与103.27%(99.25%~107.45%),血浆中二甲双胍的 Cmax、 AUC0-t、 AUC0-∞几何均数比值与 90% 置信区间分别是 101.81%(98.36%~105.38%)、98.99%(94.45%~103.75%)与 98.94%(94.48%~ 103.61%)。结论: 两种制剂在空腹和餐后给药情况下均生物等效。

Abstract

AIM: To compare the bioavailability and bioequivalence of dapagliflozin and metformin extended-release tablets in healthy Chinese subjects. METHODS: Plasma concentrations of dapagliflozin and metformin were determined using HPLC-MS/MS. Bioequivalence was analyzed using WinNonlin software (version 8.2) and SAS 9.4. RESULTS: Fasting conditions: After a single oral dose of the test or reference formulation (10 mg/1 000 mg dapagliflozin/metformin ER), the geometric mean ratios (90% confidence intervals) for dapagliflozin wereCmax: 109.18% (101.89%-116.99%); AUC0–t: 102.17% (99.37%-105.04%); AUC0–∞: 101.92% (98.94%-104.99%). For metformin the values wereCmax: 101.85% (96.67%-107.30%); AUC0–t: 100.51% (95.36%-105.95%); AUC0–∞: 100.03% (94.94%-105.39%). Fed conditions: After a single oral dose of the test or reference formulation, the geometric mean ratios (90% confidence intervals) for dapagliflozin were Cmax: 98.27% (88.80%-108.74%), AUC0–t: 103.09% (99.17%-107.16%); AUC0–∞: 103.27% (99.25%-107.45%). For metformin, the values were Cmax: 101.81% (98.36%-105.38%), AUC0–t: 98.99% (94.45%-103.75%), AUC0–∞: 98.94%(94.48%-103.61%). CONCLUSION: The two formulations are bioequivalent under both fasting and fed conditions.

关键词

达格列净二甲双胍缓释片 / 药代动力学 / 生物等效性 / 临床试验

Key words

dapagliflozin-metformin extended-release tablets / pharmacokinetics / bioequivalence / clinical trial

引用本文

引用格式 ▾
叶茜,刘一乔,吴轩宇,王一琪,李帆,李宏宇,孟祥云,王凤玲. 达格列净二甲双胍缓释片在中国健康受试者的等效性研究[J]. 中国临床药理学与治疗学, 2026, 31(9): 1231-1237 DOI:10.12092/j.issn.1009-2501.2026.09.009

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

施勇芳, 廖铁军, 邓颖玉, 等. 达格列净片联合盐酸二甲双胍缓释片治疗年轻肥胖 2 型糖尿病患者的疗效分析[J].大医生, 2022, 7(19): 94-97.

[2]

中华医学会糖尿病学分会. 中国 2 型糖尿病防治指南: 2020 年版[J].中华糖尿病杂志, 2021, 13(4): 315-409.

[3]

Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin[J].Diabetes Obes Metab, 2014, 16(2): 159-169.

[4]

国家食品药品监督管理总局. 《以药动学参数为终点评价指标的化学药物仿制药人体生物等效性研究技术指导原则》[S].2016.

[5]

国家食品药品监督管理总局. 化学药物制剂人体生物利用度和生物等效性研究技术指导原则[S].2005.

[6]

AstraZeneca AB. 达格列净二甲双胍缓释片 (Xigduo XR)FDA 原研说明书[Z]. 2022-12.

[7]

Lee HW, Kang WY, Park JS, et al. Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1, 000 mg) tablets in healthy subjects[J].Transl Clin Pharmacol, 2023, 31(2): 105-113.

[8]

Zhao X, Ning R, Hui A, et al. Pharmacokinetic variables of dapagliflozin/metformin extended-release fixed-dose combination in healthy Chinese volunteers and regional comparison[J].Clin Ther, 2023, 45(8): 762-769.

[9]

Ismail-Beigi F. Glycemic management of type 2 diabetes mellitus[J].N Engl J Med, 2012, 366: 1319-1327.

[10]

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care, 2015, 38(1): 140-149.

[11]

Cook MN, Girman CJ, Stein PP, et al. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care[J].Diabet Med, 2007, 24(4): 350-358.

[12]

Michael N. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes[J].Drug Des Devel Ther, 2014, 8: 1335-1380.

[13]

Tan XY, Hu JB.Combination therapy for type 2 diabetes: dapagliflozin plus metformin[J].Expert Opin Pharmacother, 2016, 17(1): 117-126.

[14]

邓宁, 胡庆芬, 梁彩虹, 等. 达格列净片联合盐酸二甲双胍对 2 型糖尿病患者的临床研究[J].中国临床药理学杂志, 2019, 35(18): 2016-2018,2039.

基金资助

2024 年度安徽省卫生健康科研项目(皖卫函〔2025〕69 号(AH-WJ2024Aa30029))

白求恩·肿瘤临床研究计划(BCF-XD-ZL-20220118-042)

AI Summary AI Mindmap
PDF (652KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉